Veracyte presents six ESMO studies before results for Veracyte stock

Published on 10/20/2026 at 14:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Six studies are set for ESMO on October 23, 2026. Veracyte stock trades at EUR 39.04 on October 20, 2026 during trading.

ESMO studies and upcoming dates

Veracyte announced six ESMO 2026 studies on October 19, 2026.
Second-quarter 2026 revenue reached USD 150.32 million, up 15.5 percent year over year.
Veracyte stock traded at EUR 39.04 at 2:17 p.m. CEST at Lang & Schwarz on October 20, 2026.
Third-quarter 2026 results are scheduled for November 4, 2026.

VCYT, US92337F1075, Illustration mit AI erstellt.

Veracyte (US92337F1075) announced six studies for the European Society for Medical Oncology Congress 2026, including new evidence tied to prostate, bladder and breast cancer tests. GlobeNewswire reported the announcement on October 19, 2026, giving investors a dated pipeline and evidence update ahead of the company's next results.

ESMO adds six dated studies

The presentations cover treatment selection and risk assessment across prostate, bladder and breast cancer. One oral presentation will examine whether the Decipher Prostate test predicts benefit from adding abiraterone to androgen deprivation therapy, while another will present an economic analysis of Prosigna-guided chemotherapy decisions.

Three company events set the sequence

On October 14, 2026, Veracyte scheduled third-quarter 2026 results for November 4, 2026, through GlobeNewswire. On October 16, 2026, the company announced Medicare coverage for Prosigna, effective August 19, 2026, for eligible postmenopausal women with early-stage estrogen receptor positive breast cancer, according to GlobeNewswire. On October 19, 2026, Veracyte announced the six ESMO studies through the same release channel.

What does reimbursement change?

The Medicare decision creates a reimbursement path for patients meeting criteria that include stage I or II disease with 0-3 positive lymph nodes. The company said the coverage could support broader adoption of Prosigna after its June 2026 U.S. launch, but the commercial effect will be tested against future utilization and reimbursement execution.

Revenue gives the next benchmark

For the second quarter of 2026, Veracyte reported revenue of USD 150.32 million, up 15.5 percent from the prior-year quarter, while earnings per share reached USD 0.54 versus a USD 0.41 consensus estimate, according to MarketBeat. The same report said 11 analysts carried a Moderate Buy consensus with an average USD 55.78 target, although that target reflects a range of views rather than a single forecast.

Two dates now matter

The next disclosed company date is the ESMO Congress presentation program beginning October 23, 2026, followed by third-quarter results on November 4, 2026, according to GlobeNewswire and the company's results notice.

The euro quote in afternoon trading

Veracyte was trading at EUR 39.04 at Lang & Schwarz on October 20, 2026 at 2:17 p.m. CEST. The Nasdaq-listed company had a market capitalization of USD 3.5 billion and a 52-week range of USD 29.45 to USD 60.91 as of October 19, 2026.

The further course of trading is shown by the continuously updated real-time quote of Veracyte stock.